CAMBRIDGE, Mass., July 18,
2024 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced that it will host a live conference
call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024, to report its second
quarter 2024 financial results and provide a corporate update.
To access the live conference call, please dial 833-470-1428
(domestic) or 404-975-4839 (international) and refer to conference
ID 299779. A webcast of the call will also be available under
"Events and Presentations" in the Investors & Media section of
the Blueprint Medicines website at
http://ir.blueprintmedicines.com/. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated
biopharmaceutical company that invents life-changing medicines. We
seek to alleviate human suffering by solving important medical
problems in two core focus areas: allergy/inflammation and
oncology/hematology. Our approach begins by targeting the root
causes of disease, using deep scientific knowledge in our core
focus areas and drug discovery expertise across multiple
therapeutic modalities. We have a track record of success with two
approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which
we are bringing to patients with systemic mastocytosis (SM) in the
U.S. and Europe. Leveraging our
established research, development, and commercial capability and
infrastructure, we now aim to significantly scale our impact by
advancing a broad pipeline of programs ranging from early science
to advanced clinical trials in mast cell diseases including SM and
chronic urticaria, breast cancer and other solid tumors. For more
information, visit www.BlueprintMedicines.com and follow us on
X (formerly Twitter; @BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-second-quarter-2024-financial-results-on-thursday-august-1-2024-302196224.html
SOURCE Blueprint Medicines Corporation